AdARRC™
  • Call Us: +971 2 245 0058
  • Email Us : info@adarrc.org
  • Home
  • AdARRC™
    • About Us
    • Committee
    • Future Dates of AdARRC™
    • History
      • Previous Speakers of AdARRC™
      • AdARRC Academy™
      • AdARRC Summit™
    • Annual Initiatives
      • Best Image Competition
      • Nominate a Trainee Winner
  • Registration
    • Register Now
    • Venue & Accommodation
    • UAE Visa Application
  • Call for Abstracts
  • Best Image Competition
  • Nominate a Trainee
  • Scientific Agenda
    • AdARRC Academy™
      • Fellows-in-Training Academy™
      • Immunology Academy™
      • Radiology & Rheumatology Academy™
      • Research Methodology Academy™
  • Invited Speakers
  • Sponsorship
    • Sponosors
    • Become a Sponsor or Exhibitor
×

Author: AdARRC™

 No difference in resolution of urinary tract infection symptoms with 7 vs 14 days of antibiotic therapy among afebrile men
AdARRC™ October 11, 2021 Monday Weekly Update

No difference in resolution of urinary tract infection symptoms with 7 vs 14 days of antibiotic therapy among afebrile men

Question Is 7 days of antibiotic therapy noninferior to 14 days of therapy when treating urinary tract infection symptoms in afebrile men? Conclusion This study found that 7 days of antibiotic therapy with either ciprofloxacin or trimethoprim/sulfamethoxazole is noninferior to…
Read More
 High-frequency spinal cord stimulation improves pain in patients with refractory painful diabetic neuropathy
AdARRC™ October 4, 2021 Monday Weekly Update

High-frequency spinal cord stimulation improves pain in patients with refractory painful diabetic neuropathy

Question Is high-frequency spinal cord stimulation added to conventional medical management effective in alleviating pain in persons with painful diabetic neuropathy refractory to medical therapy? Conclusion Is high-frequency spinal cord stimulation added to conventional medical management effective in alleviating pain…
Read More
 More unfavorable outcomes with 6 weeks versus 12 weeks of oral antibiotic therapy for prosthetic joint infections
AdARRC™ September 27, 2021 Monday Weekly Update

More unfavorable outcomes with 6 weeks versus 12 weeks of oral antibiotic therapy for prosthetic joint infections

Question What is the optimal duration of oral antibiotic therapy after surgical treatment for prosthetic hip or knee joint infections? Conclusion Following surgical treatment for prosthetic joint infections, a 6-week course of oral antibiotic therapy is not as effective as…
Read More
 Multiple steroid injections into arthritic joints do not improve outcomes more than other injections
AdARRC™ September 20, 2021 Monday Weekly Update

Multiple steroid injections into arthritic joints do not improve outcomes more than other injections

Question Are multiple intra-articular corticosteroid injections more effective and safer than other joint injections in patients with degenerative joint disease? Conclusion In this systematic review, patients with degenerative joint disease who received multiple corticosteroid injections did not have more meaningful…
Read More
 Type of shoe doesn’t seem to matter for moderate to severe knee osteoarthritis due to medial joint space narrowing
AdARRC™ September 13, 2021 Monday Weekly Update

Type of shoe doesn’t seem to matter for moderate to severe knee osteoarthritis due to medial joint space narrowing

Question Are flat flexible shoes as effective as stable supportive shoes to decrease pain in patients with knee osteoarthritis? Conclusion Tell patients with knee pain to experiment to see if changing their shoe type produces pain relief. In this study,…
Read More
 FDA Approved  Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus
AdARRC™ August 9, 2021 Monday Weekly Update

FDA Approved Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus

The Drug The U.S. Food and Drug Administration (FDA) has approved Saphnelo™ (anifrolumab-fnia) as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard therapy. It is the third U.S. FDA approval of a lupus therapy since…
Read More
 Rapid antigen tests for COVID-19 are much less sensitive in asymptomatic persons (40% vs 80% in symptomatic persons)
AdARRC™ June 21, 2021 Monday Weekly Update

Rapid antigen tests for COVID-19 are much less sensitive in asymptomatic persons (40% vs 80% in symptomatic persons)

Question How accurate are rapid antigen tests for COVID-19 in both asymptomatic and symptomatic patients? Conclusion A rapid antigen test (Sofia FIA from Quidel) was highly specific, but sensitivity was 80% in symptomatic patients and only 40% in asymptomatic patients.…
Read More
 Epidural steroid injections provide minimal, if any, benefit in low back pain with sciatica
AdARRC™ June 14, 2021 Monday Weekly Update

Epidural steroid injections provide minimal, if any, benefit in low back pain with sciatica

Question For patients with sciatica, do epidural corticosteroid injections safely reduce pain and disability? Conclusion Epidural corticosteroid injections provide a small and probably clinically insignificant reduction in leg and back pain in the immediate term (< 2 weeks), and a…
Read More
 Ultrasound-guided steroid injections are more accurate than blind injections for frozen shoulder, but outcomes are similar
AdARRC™ June 7, 2021 Monday Weekly Update

Ultrasound-guided steroid injections are more accurate than blind injections for frozen shoulder, but outcomes are similar

Question Are ultrasound-guided intra-articular steroid injections more accurate than blind injections? Conclusion In this study from at a single center where steroid injections were given by a single experienced clinician, ultrasound (US)-guided intra-articular injections were more accurate than blind injection.…
Read More
 Convalescent plasma does not  improve outcomes in patients  hospitalized with severe COVID-19  pneumonia (PlasmAr)
AdARRC™ May 17, 2021 Monday Weekly Update

Convalescent plasma does not improve outcomes in patients hospitalized with severe COVID-19 pneumonia (PlasmAr)

Question Does convalescent plasma improve outcomes in patients hospitalized with severe pneumonia due to SARS-CoV-2? Conclusion In this study, convalescent plasma did not improve outcomes in patients hospitalized with severe COVID-19 pneumonia. Reference Simonovich VA, Burgos Pratx LD, Scibona P,…
Read More
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7

AdARRC™

Organising Secretariat

  • K.I.T. Group Middle East FZ LLC
  • Yas Creative Hub, Tower 1
  • P.O. Box: 77893
  • Abu Dhabi, United Arab Emirates

+ 971 2 245 0058
+ 971 55 295 0283
info@adarrc.org
Monday – Friday: 9:00 AM – 06:00 PM (GMT+4)

Important Dates

Registration

  • Early Bird: 04 April 2025
  • Standard: 03 July 2025
  • Late/Onsite: 04 September 2025

Call for Abstracts

  • Submission Opens 16 April 2025
  • Submission Deadline: Closed for submissions
  • Acceptance Notification: 11 August 2025

 

Best Image

  • Submission Opens: 28 April 2025
  • Submission Deadline: Closed for submissions

Nominate a Trainee

  • Submission Opens: 29 July 2025
  • Submission Deadline: 31 August 2025

© 2025 AdARRC™. All rights reserved